OBJECTIVES: To investigate change in psychiatric disorder and change in cognitive function in patients with systemic lupus erythematosus (SLE) assessed on two occasions two years apart. METHODS: A prospective cohort study of 49 patients with SLE using standardised psychiatric and clinical research methods. RESULTS: The point prevalence of psychiatric disorder (20% and 24%), and of cognitive impairment (23% and 18%), was similar at first and second interview for the whole group. There was, however, considerable change in individual patient's psychiatric status and cognitive function: only 1/9 patients with impairment on two or more cognitive tests at first interview was still impaired at second interview. Change in cognitive function appeared to mirror change in psychiatric status. CONCLUSIONS: These findings suggest that the previously reported high prevalence of cognitive impairment in SLE may be explained by coexisting psychiatric disorder, rather than reflecting subclinical central nervous system (CNS) involvement.
OBJECTIVES: To investigate change in psychiatric disorder and change in cognitive function in patients with systemic lupus erythematosus (SLE) assessed on two occasions two years apart. METHODS: A prospective cohort study of 49 patients with SLE using standardised psychiatric and clinical research methods. RESULTS: The point prevalence of psychiatric disorder (20% and 24%), and of cognitive impairment (23% and 18%), was similar at first and second interview for the whole group. There was, however, considerable change in individual patient's psychiatric status and cognitive function: only 1/9 patients with impairment on two or more cognitive tests at first interview was still impaired at second interview. Change in cognitive function appeared to mirror change in psychiatric status. CONCLUSIONS: These findings suggest that the previously reported high prevalence of cognitive impairment in SLE may be explained by coexisting psychiatric disorder, rather than reflecting subclinical central nervous system (CNS) involvement.
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Carol M Greco; Tracy Li; Abdus Sattar; Amy H Kao; Natalya Danchenko; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi Journal: J Rheumatol Date: 2011-12-15 Impact factor: 4.666
Authors: Meggan Mackay; Mathew P Bussa; Cynthia Aranow; Aziz M Uluğ; Bruce T Volpe; Patricio T Huerta; Miklos Argyelan; Arthur Mandel; Joy Hirsch; Betty Diamond; David Eidelberg Journal: Mol Med Date: 2011-09-21 Impact factor: 6.354
Authors: Czeslawa Kowal; Lorraine A Degiorgio; Ji Y Lee; Mark A Edgar; Patricio T Huerta; Bruce T Volpe; Betty Diamond Journal: Proc Natl Acad Sci U S A Date: 2006-12-14 Impact factor: 11.205
Authors: Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz Journal: Arthritis Care Res (Hoboken) Date: 2011-04 Impact factor: 4.794
Authors: S M Weiner; A Otte; M Schumacher; R Klein; J Gutfleisch; I Brink; P Otto; E U Nitzsche; E Moser; H H Peter Journal: Ann Rheum Dis Date: 2000-05 Impact factor: 19.103
Authors: J G Hanly; M B Urowitz; L Su; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; D Isenberg; A Rahman; G S Alarcón; D D Gladman; P R Fortin; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; E Ginzler; I N Bruce; K Steinsson; M Khamashta; M Petri; S Manzi; M A Dooley; R Ramsey-Goldman; R Van Vollenhoven; O Nived; G Sturfelt; C Aranow; K Kalunian; M Ramos-Casals; A Zoma; J Douglas; K Thompson; V Farewell Journal: Ann Rheum Dis Date: 2009-04-08 Impact factor: 19.103